Skip to content

Study · Randomized controlled trial · n = 79 · 1995

5 results

Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran.

Schött U, Sollén C, Axelsson K, Rugarn P, Allvin I

Acta anaesthesiologica Scandinavica1 Jul 1995Cited by 27 (Europe PMC)

PMID7572006 (opens in a new tab)DOI10.1111/j.1399-6576.1995.tb04133.x (opens in a new tab)PepBankPUB-07572006
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hip replacement patients receiving dextran, mean blood loss did not differ significantly between desmopressin and placebo (P > 0.05).

    In plain wordsIn hip replacement patients receiving dextran, blood loss did not differ significantly between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeMean blood loss
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences (P > 0.05) in mean blood loss or transfusion requirements between the placebo and the desmopressin group.
    2 context sentences
    Summary · context
    The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis.
    Summary · context
    An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hip replacement patients receiving dextran, transfusion requirements did not differ significantly between desmopressin and placebo (P > 0.05).

    In plain wordsIn hip replacement patients receiving dextran, transfusion needs did not differ significantly between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeTransfusion requirements
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences (P > 0.05) in mean blood loss or transfusion requirements between the placebo and the desmopressin group.
    2 context sentences
    Summary · context
    The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis.
    Summary · context
    An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hip replacement patients receiving dextran, desmopressin increased vWF ristocetin cofactor activity after both infusions versus placebo (P < 0.01).

    In plain wordsIn hip replacement patients receiving dextran, desmopressin increased vWF activity more than placebo after both infusions.

    Peptide
    Desmopressin
    Outcome
    IncreasevWF ristocetin cofactor activity
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    There was a significantly increase (P < 0.01) both in vWF: ristocetin cofactor and in FVIII: C activity after both infusions of desmopressin compared with placebo.
    2 context sentences
    Summary · context
    The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis.
    Summary · context
    An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In hip replacement patients receiving dextran, desmopressin increased FVIII C activity after both infusions versus placebo (P < 0.01).

    In plain wordsIn hip replacement patients receiving dextran, desmopressin increased FVIII activity more than placebo after both infusions.

    Peptide
    Desmopressin
    Outcome
    IncreaseFVIII C activity
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    There was a significantly increase (P < 0.01) both in vWF: ristocetin cofactor and in FVIII: C activity after both infusions of desmopressin compared with placebo.
    2 context sentences
    Summary · context
    The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis.
    Summary · context
    An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In hip replacement patients receiving dextran, beta TG, tPA, PAI and Sonoclot analysis did not differ significantly between desmopressin and placebo.

    In plain wordsIn hip replacement patients receiving dextran, the reported hemostatic panel did not differ significantly between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeBeta-thromboglobulin, tPA, PAI and Sonoclot analysis
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in beta TG, tPA, PAI or Sonoclot analysis between the groups.
    2 context sentences
    Summary · context
    The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis.
    Summary · context
    An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.